Circulation

NOVEMBER 11, 2024

Background:Lipid metabolic alterations are emerging as significant mechanisms in the prognosis of cardiac remodeling induced by hypertension and could impact the therapies for cardiac fibrosis. Circulation, Volume 150, Issue Suppl_1 , Page A4140979-A4140979, November 12, 2024.

Hypertension 40

Hypertension Transplant Cardiac Function Circulation 40

Heart BMJ

MARCH 12, 2024

Background Pulmonary hypertension (PH) is a common complication in patients with complete dextro-transposition of the great arteries (TGA) after atrial switch (D-TGA/AS) and congenitally corrected TGA (ccTGA). In follow-up (median 23 months), HFHs/year were similar to the year prior to IHM (median 0 (IQR 0–1.0) before vs 0 (0–0.8)

Transplant 40

Transplant Heart Transplant Pulmonary Congenital 40

Cardiometabolic Health Congress

NOVEMBER 16, 2023

Key findings presented at the conference included disparities in access to kidney transplantation and waitlisting based on race and neighborhood characteristics, racial and ethnic differences in incident chronic kidney disease (CKD), and the use of motivational strategies to improve dialysis nonadherence among African American patients.

Kidney Disease 52

Kidney Disease Blood Pressure Diabetes Hospital 52

American College of Cardiology

MARCH 31, 2025

25 in Chicago and simultaneously published in NEJM.

Transplant 69

Transplant Outcomes Pulmonary Hypertension 69

Frontiers in Cardiovascular Medicine

FEBRUARY 19, 2025

CVDs include coronary heart disease, stroke, hypertension, and peripheral vascular diseases. Although heart transplantation can replace the damaged heart, its clinical application and promotion are limited by the source of donor, expensive cost, immune rejection, and ethical problems.

Myocardial Infarction 52

Myocardial Infarction Quality of Life Heart Transplant Ischemia 52

Open Heart

JUNE 8, 2022

Objective Pulmonary arterial hypertension (PAH), caused by pulmonary artery remodelling and increased pulmonary vascular resistance (PVR) due to an unknown mechanism, is an intractable disease with a poor prognosis. The primary outcome was death or lung transplantation.

Pulmonary 52

Pulmonary Hypertension Transplant Risk Factors 52

The New England Journal of Medicine

MARCH 30, 2025

Among adults with pulmonary arterial hypertension at high risk for death, sotatercept reduced the risk of a composite of death from any cause, lung transplantation, or hospitalization for worsening pulmonary arterial hypertension.

Pulmonary 56

Pulmonary Hypertension Transplant Hospital 56

Circulation: Cardiovascular Imaging

JANUARY 15, 2024

BACKGROUND:Advanced chronic kidney disease is associated with high cardiovascular risk, even after kidney transplant. Pretransplant cardiac testing may identify patients who require additional assessment before transplant or would benefit from risk optimization. years post-transplant. A minority had abnormal MPI (n=58, 15%).

Transplant 40

Transplant Coronary Artery Disease Myocardial Infarction Kidney Disease 40

MIBHS

OCTOBER 31, 2024

High Blood Pressure (Hypertension) Persistent high blood pressure forces the heart to work harder to pump blood. Chronic Pulmonary Disease Lung diseases like chronic obstructive pulmonary disease (COPD) can lead to pulmonary hypertension, which in turn can cause the right side of the heart to enlarge, a condition known as cor pulmonale.

Blood Pressure 52

Blood Pressure Blood Clot Heart Valves Heart Rhythm 52

Heart BMJ

NOVEMBER 27, 2023

Objective A 45% threshold of right ventricular ejection fraction (RVEF) is proposed clinically relevant in patients with pulmonary arterial hypertension (PAH). We aim to determine treatment response, long-term right ventricular (RV) functional stability and prognosis of patients with PAH reaching or maintaining the RVEF 45% threshold.

Pulmonary 52

Pulmonary Hypertension Transplant 52

Circulation: Cardiovascular Imaging

DECEMBER 16, 2024

Noninvasive surrogates for RVAC using echocardiographic estimates of right ventricular function, such as tricuspid annular plane systolic excursion (TAPSE), have been shown to correlate with invasively measured RVAC and predict clinical outcomes in pediatric pulmonary arterial hypertension.

Pediatrics 40

Pediatrics Pulmonary Congenital Heart Disease Hypertension 40

Stroke Journal

JANUARY 30, 2025

A detailed review of clinical information from the medical records was performed and included analysis of presenting symptoms, risk factors, and medical history.Results:We identified 16 cases of hypertensive encephalopathy and 32 age and sex matched controls with PRES on MRI.

Hypertension 40

Hypertension Risk Factors Transplant Strokes 40

Journal of the American Heart Association

FEBRUARY 29, 2024

BackgroundAnnual heart transplant (HT) volumes have increased, as have post‐HT outpatient care needs. days), and comorbidity burden was high: 42% had hypertension, 38% had diabetes, and 31% had ≥2 comorbidities. Journal of the American Heart Association, Ahead of Print. Length of stay was 3.1 days (interquartile range, 1.6–5.9

Heart Transplant 40

Heart Transplant Transplant Hospital Outpatient 40

DAIC

JUNE 24, 2024

PROACTIVE-HF demonstrated that with Cordella clinicians achieved more optimal and timely dosing of key HF medications, significantly improving outcomes.

Heart Failure 109

Heart Failure Reimbursement Heart Transplant Pulmonary 109

DAIC

MARCH 29, 2024

The primary effectiveness endpoint was a composite of death, heart transplant/left ventricular assist device (LVAD) implantation, HF hospitalization, outpatient HF worsening, and quality of life. This type of HF is largely associated with obesity and hypertension.

Preserved Ejection Fraction 111

Preserved Ejection Fraction Heart Failure Quality of Life Hospital 111

Stroke Journal

JANUARY 30, 2025

We induced intracranial aneurysms on chimeric mice with partial bone marrow transplantation of TET2-knockout hematopoietic stem cells, widely used to recapitulate human CHIP to test our hypothesis.Methods:We used competitive bone marrow transplantation as a model of CHIP. We used the C57BL/6 congenic mice that express the CD45.1

Aneurysm 40

Aneurysm Transplant Risk Factors Cancer 40

Cardiometabolic Health Congress

AUGUST 8, 2024

Key contributions: Advanced cardiac imaging (e.g., high-sensitivity troponin, NT-proBNP) in risk stratification Utilization of advanced echocardiographic techniques (e.g.,

Education 59

Education Cardiovascular Disease Diabetes Kidney Disease 59

Society of Thoracic Surgeons - Research

APRIL 20, 2023

Part 1: Concepts, Indicator Variables, and Controversies The Annals of Thoracic Surgery January 2022 Arman Kilic Supplementing Existing Societal Risk Models for Surgical Aortic Valve Replacement With Machine Learning for Improved Prediction Journal of the American Heart Association November 2021 Jared Belle Strategies for Mechanical Right Ventricular (..)

Research 52

Research Coronary Artery Bypass Graft Aortic valve Congenital 52

Society of Thoracic Surgeons - Research

APRIL 20, 2023

Institutional Coronary Artery Bypass Case Volumes and Outcomes European Journal of Heart Failure October 2023 Makoto Mori 1 Robotic Mitral Valve Repair for Degenerative Mitral Regurgitation The Annals of Thoracic Surgery August 2023 Carlos Diaz-Castrillion 2 Volume-Failure to Rescue Relationship in Acute Type A Aortic Dissections: An Analysis of The (..)

Research 52

Research Coronary Artery Bypass Graft Aortic valve Congenital 52

CardiacWire

NOVEMBER 27, 2024

Stunning topline results from Merck Winrevair’s Phase 3 ZENITH trial found that the drug significantly reduced morbidity and mortality risks in patients with pulmonary arterial hypertension, paving the way for stronger commercialization and further functional trials. Adverse events weren’t serious, but headache (24.5%

Blood Pressure 52

Blood Pressure Pulmonary Transplant Hypertension 52